| Subjects | Hazard ratio (95% CI) | p-value |
Age years | | | |
<65 | 93 | 1 | |
≥65 | 93 | 1.365 (0.927–2.008) | 0.115 |
Sex | | | |
Male | 115 | 1 | |
Female | 71 | | 0.378 |
Smoking status | | | |
Current and ex-smokers | 175 | 1 | |
Never-smokers | 11 | 1.46 (0.677–3.151) | 0.334 |
Type of surgery | | | 0.865 |
Lobectomy | 137 | 1 | |
Bilobectomy | 17 | 0.723 (0.442–1.761) | 0.883 |
Pneumonectomy | 32 | 0.654 (0.525–1.499) | 0.887 |
Tumour size | | | |
<5 cm | 124 | 1 | |
≥5 cm | 62 | 2.155 (1.456–3.189) | <0.001 |
Tumour stage | | | |
T1 | 40 | 1 | |
T2 and T3 | 146 | 1.671 (0.993–2.810) | 0.053 |
Node stage | | | |
N0 | 114 | 1 | |
N1 and N2 | 72 | 1.527 (1.037–2.249) | 0.032 |
WHO overall pathological stage | | | 0.002 |
IA and IB | 103 | 1 | |
IIA and IIB | 44 | 1.358 (0.837–2.203) | 0.215 |
IIIA | 39 | 2.296 (1.458–3.614) | 0.000 |
Tumour grade | | | 0.699 |
1 | 13 | 1 | |
2 | 110 | 0.745 (0.369–1.504) | 0.411 |
3 | 63 | 0.808 (0.389–1.679) | 0.567 |
Histological subtype | | | 0.868 |
Squamous | 85 | 1 | |
Adenocarcinoma | 84 | 1.036 (0.691–1.552) | 0.865 |
Large cell | 5 | 1.111 (0.346–3.574) | 0.859 |
Mixed | 12 | 1.408 (0.635–3.122) | 0.400 |
Surgical resection margins | | | |
Negative | 163 | 1 | |
Positive | 23 | 2.259 (1.355–3.766) | 0.002 |
EGFR mutation | | | |
Negative | 175 | 1 | |
Positive | 11 | 0.71 (0.255–1.976) | 0.5 |
KRAS mutation | | | |
Negative | 175 | 1 | |
Positive | 11 | 1.36 (0.582–3.171) | 0.47 |
TI/S CD3+ | | | |
<Median | 86 | 1 | |
≥Median | 88 | 0.703 (0.470–1.05) | 0.086 |
TI/S CD8+ | | | |
<Median | 88 | 1 | |
≥Median | 91 | 0.440 (0.292–0.665) | <0.001 |
TI/S Foxp3+ | | | |
<Median | 90 | 1 | |
≥Median | 86 | 4.860 (3.112–7.588) | <0.001 |